

Jean-Francois Tanguay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7687215/publications.pdf>

Version: 2024-02-01

68

papers

2,885

citations

279798

23

h-index

168389

53

g-index

68

all docs

68

docs citations

68

times ranked

3775

citing authors

#	ARTICLE	IF	CITATIONS
1	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. <i>Lancet, The</i> , 2010, 376, 1233-1243.	13.7	725
2	Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2211-2221.	2.8	240
3	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2018, 138, 527-536.	1.6	211
4	Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 629-638.	2.8	190
5	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. <i>Canadian Journal of Cardiology</i> , 2018, 34, 214-233.	1.7	181
6	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 583-596.	1.6	119
7	Estrogen Regulation of Endothelial and Smooth Muscle Cell Migration and Proliferation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1585-1590.	2.4	110
8	The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. <i>Canadian Journal of Cardiology</i> , 2011, 27, S1-S59.	1.7	106
9	Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1334-1345.	1.7	97
10	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	83
11	Right Atrial Mechanisms of Atrial Fibrillation in a Rat Model of Right Heart Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1332-1347.	2.8	72
12	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y ₁₂ receptor antagonist, in patients with chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 3132-3140.	2.2	52
13	Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1552-1562.	2.9	51
14	Coronary artery endothelial protection after local delivery of 17 β -estradiol during balloon angioplasty in a porcine model: a potential new pharmacologic approach to improve endothelial function. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1570-1576.	2.8	50
15	Nature of fatty acids in high fat diets differentially delineates obesity-linked metabolic syndrome components in male and female C57BL/6J mice. <i>Diabetology and Metabolic Syndrome</i> , 2011, 3, 34.	2.7	47
16	Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. <i>Circulation</i> , 2016, 133, 1772-1782.	1.6	47
17	Transapical Mitral Implantation of the Tiara Bioprosthesis. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 154-162.	2.9	39
18	The inflammation-resolution promoting molecule resolvin-D1 prevents atrial proarrhythmic remodelling in experimental right heart disease. <i>Cardiovascular Research</i> , 2021, 117, 1776-1789.	3.8	38

#	ARTICLE	IF	CITATIONS
19	Evaluation of a Web-Based E-Learning Platform for Brief Motivational Interviewing by Nurses in Cardiovascular Care: A Pilot Study. <i>Journal of Medical Internet Research</i> , 2016, 18, e224.	4.3	37
20	Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008603.	3.9	28
21	A cardiovascular monitoring system used in conscious cynomolgus monkeys for regulatory safety pharmacology: Part 2: Pharmacological validation. <i>Journal of Pharmacological and Toxicological Methods</i> , 2007, 56, 122-130.	0.7	27
22	Estradiol inhibits vascular endothelial cells pro-inflammatory activation induced by C-reactive protein. <i>Molecular and Cellular Biochemistry</i> , 2013, 373, 137-147.	3.1	27
23	Increased Uptake of Guideline-Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1725-1731.	1.7	26
24	A Comparison of prasugrel at the time of percutaneous Coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: Design and rationale for the ACCOAST study. <i>American Heart Journal</i> , 2011, 161, 650-656.e1.	2.7	23
25	Prognostic impact of the residual SYNTAX score on in-hospital outcomes in patients undergoing primary percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 740-747.	1.7	22
26	Local delivery of 17 β -estradiol improves reendothelialization and decreases inflammation after coronary stenting in a porcine model. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1042-1047.	3.4	21
27	Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 2094-2098.	1.6	19
28	Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 190-198.	1.7	18
29	Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. <i>Heart</i> , 2015, 101, 1219-1224.	2.9	15
30	Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y ₁₂ receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 543-553.	1.0	15
31	A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1298-1307.	1.7	12
32	2-Dioleoyl-sn-glycero-3-phosphocholine-based nanoliposomes as an effective delivery platform for 17 β -estradiol. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 369-375.	4.3	11
33	Repair of left anterior descending coronary artery perforation by magic wallstent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 1999, 48, 304-307.	1.7	9
34	Bioresorbable Vascular Scaffold During ST-Elevation Myocardial Infarction: A Systematic Review. <i>Canadian Journal of Cardiology</i> , 2017, 33, 515-524.	1.7	9
35	Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy. <i>CJC Open</i> , 2020, 2, 118-128.	1.5	9
36	Microwave-assisted synthesis of surface-enhanced Raman scattering nanoprobe for cellular sensing. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 122, 617-622.	5.0	8

#	ARTICLE	IF	CITATIONS
37	Platelet function testing as a biomarker for efficacy of antiplatelet drugs. <i>Biomarkers in Medicine</i> , 2016, 10, 903-918.	1.4	8
38	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. <i>Thrombosis and Haemostasis</i> , 2019, 119, 576-585.	3.4	8
39	Vascular healing after stenting: the role of 17-beta-estradiol in improving re-endothelialization and reducing restenosis. <i>Canadian Journal of Cardiology</i> , 2005, 21, 1025-30.	1.7	7
40	Key Fatty Acid Combinations Define Vascular Smooth Muscle Cell Proliferation and Viability. <i>Lipids</i> , 2012, 47, 1073-1084.	1.7	6
41	The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey. <i>Canadian Journal of Cardiology</i> , 2022, 38, S79-S88.	1.7	6
42	Verifying Death Reports in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Journal of Therapeutics</i> , 2020, 27, e563-e572.	0.9	5
43	Novel Artificial Intelligence Applications in Cardiology: Current Landscape, Limitations, and the Road to Real-World Applications. <i>Journal of Cardiovascular Translational Research</i> , 2023, 16, 513-525.	2.4	5
44	Longer Inflation Duration and Predilation "Sizing" Postdilation Improve Bioresorbable Scaffold Outcomes in a Long-term All-Comers Canadian Registry. <i>Canadian Journal of Cardiology</i> , 2018, 34, 752-758.	1.7	4
45	A web-based tailored nursing intervention (TAVIE en m@rche) aimed at increasing walking after an acute coronary syndrome: Multicentre randomized trial. <i>Journal of Advanced Nursing</i> , 2019, 75, 2727-2741.	3.3	4
46	Isolating and expanding endothelial progenitor cells from peripheral blood on peptide-functionalized polystyrene surfaces. <i>Biotechnology and Bioengineering</i> , 2019, 116, 2598-2609.	3.3	4
47	Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual) <i>TJ ETQq1 1 0.784314 rgBT₄/Overlook</i>	1.6	4
48	Everolimus-eluting bioresorbable vascular scaffold implantation to treat saphenous vein graft disease, single-center initial experience. <i>Journal of Interventional Cardiology</i> , 2017, 30, 433-439.	1.2	3
49	Early Multiple Coronary Micro Aneurysms After Bioresorbable Vascular Scaffold Implantation. <i>Canadian Journal of Cardiology</i> , 2017, 33, 292.e9-292.e11.	1.7	3
50	Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada. <i>CJC Open</i> , 2021, 3, 814-821.	1.5	3
51	Evaluation of a Web-Based Tailored Nursing Intervention (TAVIE en m@rche) Aimed at Increasing Walking After an Acute Coronary Syndrome: A Multicenter Randomized Controlled Trial Protocol. <i>JMIR Research Protocols</i> , 2017, 6, e64.	1.0	3
52	Antiplatelet Therapy in Acute Coronary Syndrome and Atrial Fibrillation: Aspirin. <i>Advances in Cardiology</i> , 2012, 47, 20-30.	2.7	2
53	Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial. <i>Journal of Thoracic Disease</i> , 2017, 9, E440-E443.	1.4	2
54	Clinical outcomes of bioresorbable vascular scaffold to treat all-comer patients. Are patients with acute coronary syndrome better candidates for bioresorbable vascular scaffold?. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 228-234.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Platelet Quiescence in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Bypass Graft Surgery. <i>Journal of the American Heart Association</i> , 2021, 10, e016602.	3.7	2
56	The FDA and PLATO Investigators death lists: Call for a match. <i>International Journal of Clinical Practice</i> , 2021, 75, e14105.	1.7	2
57	Late (> 48 hr) myocardial infarction after PTCA: Clinical and angiographic characteristics of infarction related or not to the angioplasty site. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 53, 155-162.	1.7	1
58	Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 939-953.	1.5	1
59	Bioresorbable vascular scaffold to treat in-stent restenosis: Single-center experience. <i>Journal of Interventional Cardiology</i> , 2017, 30, 558-563.	1.2	1
60	Long-term outcomes of bioresorbable vascular scaffold in ST-elevation myocardial infarction. <i>Acta Cardiologica</i> , 2018, 73, 276-281.	0.9	1
61	Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation: Findings from the CONNECT AF+PCI study. <i>CJC Open</i> , 2021, 3, 1419-1427.	1.5	1
62	Abstract 13993: Impact of Prasugrel Pretreatment and Timing of Coronary Artery Bypass Grafting on Clinical Outcomes of Patients With Non-ST-Segment Elevation Myocardial Infarction: From the Accoast Study. <i>Circulation</i> , 2014, 130, .	1.6	1
63	A Web-Based Tailored Intervention to Support Illness Management in Patients With an Acute Coronary Syndrome: Pilot Study. <i>JMIR Cardio</i> , 2017, 1, e4.	1.7	1
64	Infections Deaths in the PLATO Trial. <i>TH Open</i> , 2021, 05, e503-e506.	1.4	1
65	Immediate Versus Delayed Invasive Intervention for Non-ST-Segment Elevation Myocardial Infarction Patients (RIDDLE-NSTEMI Study). <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1415-1416.	2.9	0
66	Percutaneous Coronary Interventions in Patients Requiring Long-Term Oral Anticoagulation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1643-1645.	2.9	0
67	Targeted Temperature Management After Cardiac Arrest: The Montreal Heart Institute Experience. <i>CJC Open</i> , 2019, 1, 238-244.	1.5	0
68	Dual Antiplatelet Therapy after PCI: When Could We Go Shorter?. , 0, , .		0